Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting

1 Jul 2025

Abstract excerpt

This 22-month cohort study investigated the durability and dynamics of humoral immune responses in 327 Malaysians vaccinated with either CoronaVac or BNT162b2 in early 2021, monitored up to 52 weeks following a BNT162b2 booster. Using the ImmuSAFE™ COVID + microarray, we evaluated IgG-S and NAb against Wuhan-Hu and VoCs (Alpha, Beta, Delta, Omicron), as well as IgG-N responses to Wuhan-Hu. BNT162b2 induced higher...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40594462
DOI: 10.1038/s41598-025-05377-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boostingPMID 40594462Read ↗

Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes OmicronSemantic proximity Read ↗

Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trialSemantic proximity Read ↗

Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 MonthsSemantic proximity Read ↗

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infectionSemantic proximity Read ↗

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster doseSemantic proximity Read ↗

Class switch toward IgG2 and IgG4 is more pronounced in BNT162b2 compared to mRNA-1273 COVID-19 vaccineesSemantic proximity Read ↗

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster doseSemantic proximity Read ↗

Genetic immune response and antibody repertoire of heterologous ChAdOx1-BNT162b2 vaccination in a Korean cohortSemantic proximity Read ↗

Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case seriesSemantic proximity Read ↗

Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)Semantic proximity Read ↗

The BTN162b2 Vaccine Induces Humoral and Cellular Immune Memory to Wuhan Strain SARS-CoV-2 and the Omicron Variant in Children 5 to 11 Years of AgeSemantic proximity Read ↗

Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.